cefadroxil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 526 50370-12-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefadroxil
  • cefadrox
  • cephadroxil
  • cefadroxil hemihydrate
Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.
  • Molecular weight: 363.39
  • Formula: C16H17N3O5S
  • CLOGP: -2.51
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 4
  • TPSA: 132.96
  • ALOGS: -2.96
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Bocci G, Oprea TI, Benet LZ
S (Water solubility) 1 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 93 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 78.62 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.23 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.39 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 17, 1978 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cross sensitivity reaction 384.50 26.84 69 2803 2093 63484057
Type IV hypersensitivity reaction 247.76 26.84 50 2822 2848 63483302
Drug hypersensitivity 107.62 26.84 98 2774 310589 63175561
Nasal oedema 105.02 26.84 22 2850 1500 63484650
Rash maculo-papular 104.71 26.84 43 2829 31853 63454297
Oedema 73.69 26.84 49 2823 97573 63388577
Urticaria thermal 58.53 26.84 11 2861 428 63485722
Asthma 53.47 26.84 45 2827 127516 63358634
Respiratory tract infection 52.40 26.84 29 2843 41454 63444696
Administration site erythema 46.72 26.84 10 2862 755 63485395
Vitamin B12 deficiency 35.21 26.84 12 2860 5291 63480859
Pigmentation disorder 32.78 26.84 11 2861 4628 63481522
Scratch 32.71 26.84 12 2860 6553 63479597
Wheezing 32.55 26.84 30 2842 95565 63390585
Cough 31.26 26.84 51 2821 292692 63193458
Pain 31.01 26.84 88 2784 740540 62745610
Skin plaque 29.95 26.84 12 2860 8308 63477842
Iodine allergy 29.86 26.84 7 2865 797 63485353
Dizziness postural 27.80 26.84 11 2861 7365 63478785
Chest pain 27.75 26.84 41 2831 215918 63270232
Veillonella infection 27.01 26.84 4 2868 34 63486116

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cross sensitivity reaction 180.54 26.35 30 658 1367 34954876

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cross sensitivity reaction 545.05 24.20 99 3135 3613 79737541
Type IV hypersensitivity reaction 259.16 24.20 54 3180 4027 79737127
Nasal oedema 98.94 24.20 21 3213 1703 79739451
Drug hypersensitivity 93.50 24.20 85 3149 298831 79442323
Rash maculo-papular 88.90 24.20 44 3190 56034 79685120
Oedema 78.96 24.20 53 3181 119527 79621627
Asthma 68.58 24.20 51 3183 135044 79606110
Urticaria thermal 59.58 24.20 11 3223 434 79740720
Administration site erythema 55.02 24.20 10 3224 361 79740793
Respiratory tract infection 45.69 24.20 27 3207 48662 79692492
Drug reaction with eosinophilia and systemic symptoms 38.83 24.20 27 3207 64217 79676937
Pain 36.80 24.20 85 3149 703717 79037437
Erythema 36.41 24.20 45 3189 223245 79517909
Pigmentation disorder 31.89 24.20 11 3223 5607 79735547
Scratch 31.16 24.20 12 3222 8351 79732803
Toxic epidermal necrolysis 29.93 24.20 20 3214 44561 79696593
Urticaria 29.65 24.20 37 3197 185164 79555990
Vitamin B12 deficiency 29.17 24.20 11 3223 7230 79733924
Skin plaque 28.24 24.20 12 3222 10733 79730421
Cough 26.92 24.20 51 3183 366738 79374416
Wheezing 26.60 24.20 28 3206 116636 79624518
Veillonella infection 26.27 24.20 4 3230 47 79741107
Anaphylactic reaction 24.45 24.20 23 3211 83720 79657434
Secretion discharge 24.40 24.20 12 3222 15010 79726144
Dizziness postural 24.21 24.20 11 3223 11538 79729616

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DB05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
First-generation cephalosporins
CHEBI has role CHEBI:36047 antibacterial drugs
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Infection of skin AND/OR subcutaneous tissue indication 19824006
Streptococcal tonsillitis indication 41582007
Klebsiella cystitis indication 60867007
Urinary tract infectious disease indication 68566005
Tonsillitis indication 90176007 DOID:10456
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Infection due to Staphylococcus aureus indication 406602003
Prevention of Bacterial Endocarditis off-label use
Impaired renal function disorder contraindication 197663003
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Skin and soft tissue infections caused by susceptible strains of Staphylococcus aureus Indication
Cats Genitourinary tract infections caused by Escherichia coli Indication
Cats Genitourinary tract infections caused by Proteus species Indication
Cats Genitourinary tract infections caused by Staphylococcus aureus Indication
Cats Skin and soft tissue infections caused by Pasteurella multocida Indication
Cats Skin and soft tissue infections caused by Staphylococcus epidermidis Indication
Cats Skin and soft tissue infections caused by Streptococcus species Indication
Dogs Skin and soft tissue infections caused by Staphylococcus aureus Indication
Dogs Genitourinary tract infections caused by Escherichia coli Indication
Dogs Genitourinary tract infections caused by Proteus species Indication
Dogs Genitourinary tract infections caused by Staphylococcus aureus Indication

🐶 Veterinary products

ProductApplicantIngredients
Cefa-Tabs HQ Specialty Pharma Corp. 1
Cefa-Drops HQ Specialty Pharma Corp. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.77 acidic
pKa2 9.72 acidic
pKa3 13.53 acidic
pKa4 7.63 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Solute carrier family 15 member 1 Transporter Ki 2.14 WOMBAT-PK
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4018151 VUID
N0000146488 NUI
D00257 KEGG_DRUG
119922-85-9 SECONDARY_CAS_RN
1297878 RXNORM
C0007538 UMLSCUI
CHEBI:53667 CHEBI
CHEMBL1644 ChEMBL_ID
DB01140 DRUGBANK_ID
D002434 MESH_DESCRIPTOR_UI
47965 PUBCHEM_CID
4831 IUPHAR_LIGAND_ID
280111G160 UNII
d00080 MMSL
13414000 SNOMEDCT_US
372651006 SNOMEDCT_US
4018151 VANDF
66592-87-8 SECONDARY_CAS_RN
004959 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0093-3196 CAPSULE 500 mg ORAL ANDA 22 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0093-3196 CAPSULE 500 mg ORAL ANDA 22 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0093-4059 TABLET 1000 mg ORAL ANDA 23 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9766 POWDER, FOR SUSPENSION 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9767 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9947 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9948 TABLET, FILM COATED 1 g ORAL ANDA 23 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 10544-135 CAPSULE 500 mg ORAL ANDA 19 sections
CEFADROXIL Human Prescription Drug Label 1 16590-043 CAPSULE 500 mg ORAL ANDA 23 sections
Cefadroxil Human Prescription Drug Label 1 16714-388 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 16714-388 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 16714-389 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 16714-389 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 16714-390 POWDER, FOR SUSPENSION 500 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 16714-390 POWDER, FOR SUSPENSION 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 21695-427 CAPSULE 500 mg ORAL ANDA 22 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 33261-018 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 42254-146 CAPSULE 500 mg ORAL ANDA 19 sections
CEFADROXIL Human Prescription Drug Label 1 42549-504 CAPSULE 500 mg ORAL ANDA 23 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 43063-553 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 43063-553 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 43063-553 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 43063-595 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 43063-595 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 43063-595 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 45865-503 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 50090-0580 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 50090-0580 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil Human Prescription Drug Label 1 50090-1915 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 50090-6050 CAPSULE 500 mg ORAL ANDA 21 sections